|
Nov 18, 2021
|
Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference
|
|
|
Nov 04, 2021
|
Dynavax Reports Third Quarter 2021 Financial Results
|
|
|
Nov 02, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Oct 21, 2021
|
Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
|
|
|
Oct 21, 2021
|
Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
|
|
|
Oct 18, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Oct 18, 2021
|
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
|
|
|
Oct 04, 2021
|
Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant
|
|
|
Oct 01, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 27, 2021
|
Dynavax to Present at Upcoming Investment Conferences
|
|
